血液 (JP Patent Analysis Report)
The Technical Field "血液" had 1,214 patent application filings in the most recent period (2022-01-01 to 2022-08-31). This is a significantly decreased of -956 filings (-44.1%) over 2,170 they had in the same period of the previous year (2021-01-01 to 2021-08-31). This report also includes technical terms related to " 血 ", " ブラッド " in the search set.
The highest number of filings in 2016 with 4,629 cases, and their lowest number in 2022 with 1,364 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 16,807 cases in total) is 2,801, and the median is 3,363. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
| Index | Value |
|---|---|
| Average | 2,801 patents |
| Std Dev | 1,551 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 1,364 cases | -58.2 % |
| 2021 year | 3,262 cases | -5.83 % |
| 2020 year | 3,464 cases | -17.17 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 血液 for the period of the last 10 years (2014-01-01 to 2024-04-30). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 血液, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
Introduction
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
血液, Changes in the Number of JP Patents/Patent Applications
The changes in the number of patent filings of 血液 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
Search Set (Analysis Patents)
This patent analysis report was created for a patent search set of 34,472 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
血液
Same industry / competition company information (JP)
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 血液 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
Comparing the number of applications of each company, テルモ株式会社 has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 28 cases, followed by ニプロ株式会社 with 25 cases.
| Name | Cases |
|---|---|
| テルモ株式会社 | 28 cases |
| ニプロ株式会社 | 25 cases |
| キヤノンメディカルシステムズ株式会社 | 20 cases |
| エフホフマン-ラロシュアーゲー | 17 cases |
| 日機装株式会社 | 12 cases |
| ノバルティスアーゲー | 10 cases |
| コーニンクレッカフィリップスエヌヴェ | 10 cases |
| シスメックス株式会社 | 10 cases |
| 東レ株式会社 | 9 cases |
| 株式会社東芝 | 1 cases |
| 株式会社日立製作所 | 1 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
Comparing the number of applications of each company, テルモ株式会社 has the highest number of joint applications in the last for the target period (2014 to 2024) with 408 cases, followed by ノバルティスアーゲー with 311 cases.
| Name | Cases |
|---|---|
| テルモ株式会社 | 408 cases |
| ノバルティスアーゲー | 311 cases |
| コーニンクレッカフィリップスエヌヴェ | 290 cases |
| エフホフマン-ラロシュアーゲー | 275 cases |
| キヤノンメディカルシステムズ株式会社 | 239 cases |
| シスメックス株式会社 | 211 cases |
| 日機装株式会社 | 211 cases |
| 東レ株式会社 | 183 cases |
| ニプロ株式会社 | 173 cases |
| 株式会社日立製作所 | 66 cases |
| 株式会社東芝 | 15 cases |
Same industry / competition company, Change in the Number of JP Patents
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
Top company information (JP)
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 血液 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Trends in filing of joint patent applications in the last 3 years (2022 to 2024).
Among the top coapplicants, テルモ株式会社 has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 28 cases, followed by エフホフマン-ラロシュアーゲー with 17 cases.
| Name | Cases |
|---|---|
| テルモ株式会社 | 28 cases |
| エフホフマン-ラロシュアーゲー | 17 cases |
| ノバルティスアーゲー | 10 cases |
| コーニンクレッカフィリップスエヌヴェ | 10 cases |
| シスメックス株式会社 | 10 cases |
| 東レ株式会社 | 9 cases |
| 株式会社東芝 | 1 cases |
Trends in filing of joint patent applications for the target period (2014 to 2024).
Among the top coapplicants, テルモ株式会社 has the highest number of joint applications in the last for the target period (2014 to 2024) with 408 cases, followed by ノバルティスアーゲー with 311 cases.
| Name | Cases |
|---|---|
| テルモ株式会社 | 408 cases |
| ノバルティスアーゲー | 311 cases |
| コーニンクレッカフィリップスエヌヴェ | 290 cases |
| エフホフマン-ラロシュアーゲー | 275 cases |
| シスメックス株式会社 | 211 cases |
| 東レ株式会社 | 183 cases |
| 株式会社東芝 | 15 cases |
Top company, Change in the Number of JP Patents
Below is a ranking of the number of JP patent applications by 血液’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 血液’s top 7 coapplicants over the last 20 years.
Top company Details (JP)
Trends in filing of joint patent applications with テルモ株式会社
血液 filed 408 joint applications with テルモ株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 214 cases in total) is 35.7, and the median is 39.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2019 with 61 cases, and their lowest number in 2021 with 19 cases.
| Index | Value |
|---|---|
| Average | 35.7 patents |
| Std Dev | 21.9 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 28 cases | +47.4 % |
| 2021 year | 19 cases | -62.0 % |
| 2020 year | 50 cases | -18.03 % |
Trends in filing of joint patent applications with 株式会社東芝
血液 filed 15 joint applications with 株式会社東芝 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 8 cases in total) is 1.3, and the median is 1.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2014 with 4 cases, and their lowest number in 2017 with 0 cases.
| Index | Value |
|---|---|
| Average | 1.3 patents |
| Std Dev | 0.7 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 1 cases | -50.0 % |
| 2021 year | 2 cases | 0 |
| 2020 year | 2 cases | 0 |
Trends in filing of joint patent applications with ノバルティスアーゲー
血液 filed 311 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 116 cases in total) is 19.3, and the median is 16.5. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2016 with 65 cases, and their lowest number in 2022 with 10 cases.
| Index | Value |
|---|---|
| Average | 19.3 patents |
| Std Dev | 13.4 |
| COV | 0.7 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 10 cases | -44.4 % |
| 2021 year | 18 cases | +20.00 % |
| 2020 year | 15 cases | -55.9 % |
Trends in filing of joint patent applications with エフホフマン-ラロシュアーゲー
血液 filed 275 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 120 cases in total) is 20.0, and the median is 20.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2014 with 48 cases, and their lowest number in 2021 with 15 cases.
| Index | Value |
|---|---|
| Average | 20.0 patents |
| Std Dev | 11.2 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 17 cases | +13.33 % |
| 2021 year | 15 cases | -37.5 % |
| 2020 year | 24 cases | -29.41 % |
Trends in filing of joint patent applications with コーニンクレッカフィリップスエヌヴェ
血液 filed 290 joint applications with コーニンクレッカフィリップスエヌヴェ for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 118 cases in total) is 19.7, and the median is 23.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2016 with 49 cases, and their lowest number in 2022 with 10 cases.
| Index | Value |
|---|---|
| Average | 19.7 patents |
| Std Dev | 11.8 |
| COV | 0.6 |
| Year | Cases | YOY |
|---|---|---|
| 2022 year | 10 cases | -54.5 % |
| 2021 year | 22 cases | -12.00 % |
| 2020 year | 25 cases | +4.17 % |
Information on important patents (JP)
The following shows JP patents held by 血液 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 血液’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 血液 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
Glossary
- Cited
- Indicates that the patent/patent application has been cited (by Examiners) in notices of reasons for rejection in the examination process of other (Japanese, U.S., or European) patent applications. The higher the number of citations, the more important the patent/patent application is considered to be.
- Request for invalidation trial
- Indicates that a third party has requested a procedure to invalidate the patent. It is likely to affect the business of third parties and is considered to be of high importance.
- Opposition
- Indicates that a third party has filed a petition with the Patent Office to hear the validity of the patent again. Like the trial for invalidation, it is considered to be of high importance.
- Information provision
- Indicates that a third party has provided the Patent Office with useful information for examination for the patent filed. It is usually considered to be of high importance because it is done to prevent the patent from being granted.
- Browsing request
- Indicates that a third party has requested the Patent Office to view the patent bag (a set of documents exchanged between the Patent Office and the applicant). The bag is often checked prior to trial for invalidation, opposition, and provision of information, and is considered to be a highly important patent.
Invalidationed Trial cases
List of latest Invalidationed Trial patents
In the last 3 years (2021-05-01 ~ 2024-04-30), there were 10 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.1 times. The most recently Invalidation Trial patent is 特許6290627 "メトホルミン治療に不適切な患者における糖尿病の治療" (Invalidation Trial day 2023-09-07) , next is 特許7185426 "Ｓ１Ｐ受容体モジュレーターの投与計画" (Invalidation Trial day 2023-07-10) .
| - | No. | Title | Invalidation Trial days |
|---|---|---|---|
| 1 | 特許6290627 | メトホルミン治療に不適切な患者における糖尿病の治療 | 2023-09-07 |
| 2 | 特許7185426 | Ｓ１Ｐ受容体モジュレーターの投与計画 | 2023-07-10 |
| 3 | 特許5927146 | ＤＰＰ ＩＶインヒビターの使用 | 2023-07-10 |
| 4 | 特許5734564 | ＤＰＰ ＩＶインヒビターの使用 | 2023-07-10 |
| 5 | 特許5474043 | （＋）−２−［１−（３−エトキシ−４−メトキシフェニル）−２−メチルスルホニルエチル］−４−アセチルアミノイソインドリン−１，３−ジオンを含む固形物形態、その組成物およびその使用 | 2023-05-31 |
| 6 | 特許7016341 | ＰＤ－１軸結合アンタゴニスト及びＴＩＧＩＴ阻害剤を使用するがんの治療方法 | 2023-03-27 |
| 7 | 特許5813293 | ＤＰＰ ＩＶインヒビターの使用 | 2023-03-07 |
| 8 | 特許6278598 | 細胞傷害誘導治療剤 | 2022-03-31 |
| 9 | 特許4874482 | アスピリンを含有する医薬組成物 | 2022-02-22 |
| 10 | 特許6738314 | ＢＣＭＡおよびＣＤ３に対する結合分子 | 2021-07-02 |
Top Patents/Patent Applications with the Highest Number of Invalidationed Trial
Of the patent applications filed in the last 10 years (2014-05-01 to 2024-04-30), 4 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.2. The most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン９型（ＰＣＳＫ９）に対する抗原結合タンパク質" (2 times) , and the next most invalidation trial patent is 特許7016341 "ＰＤ－１軸結合アンタゴニスト及びＴＩＧＩＴ阻害剤を使用するがんの治療方法" (1 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン９型（ＰＣＳＫ９）に対する抗原結合タンパク質 | 2 times |
| 2 | 特許7016341 | ＰＤ－１軸結合アンタゴニスト及びＴＩＧＩＴ阻害剤を使用するがんの治療方法 | 1 times |
| 3 | 特許6093829 | ランタン化合物を含む医薬組成物 | 1 times |
| 4 | 特許6293103 | 自己緩衝タンパク質製剤 | 1 times |
Oppositioned cases
List of latest Oppositioned patents
In the last 3 years (2021-05-01 ~ 2024-04-30), there were 31 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7298844 "細胞培養物の製造方法" (Opposition day 2023-12-26) , next is 特許7289655 "ＰＡＭＰＳ及びＤＡＭＰＳの除去への血液適合性多孔性ポリマービーズ吸着剤の使用" (Opposition day 2023-12-12) .
| - | No. | Title | Opposition days |
|---|---|---|---|
| 1 | 特許7298844 | 細胞培養物の製造方法 | 2023-12-26 |
| 2 | 特許7289655 | ＰＡＭＰＳ及びＤＡＭＰＳの除去への血液適合性多孔性ポリマービーズ吸着剤の使用 | 2023-12-12 |
| 3 | 特許7270912 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 | 2023-11-13 |
| 4 | 特許7244922 | 化学修飾された一本鎖ＲＮＡ編集オリゴヌクレオチド | 2023-09-20 |
| 5 | 特許7237544 | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 | 2023-09-11 |
| 6 | 特許7210036 | アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法 | 2023-07-20 |
| 7 | 特許7203488 | 血液透析装置 | 2023-07-12 |
| 8 | 特許7193526 | 浴室環境で使用するバイオモニタリング・デバイス、方法、及びシステム | 2023-06-20 |
| 9 | 特許7119328 | 圧力測定用チャンバ | 2023-02-02 |
| 10 | 特許7097312 | 液体含浸表面を利用した装置および方法 | 2023-01-06 |
Protested cases
List of latest Protested patents
In the last 3 years (2021-05-01 ~ 2024-04-30), there were 85 patents Protest from third parties. The average number of Protest is 1.4 times. The most recently Protest patent is 特表2021-527040 "カンプトテシンコンジュゲート" (Protest day 2024-03-25) , next is 特表2023-546593 "ペットフード組成物" (Protest day 2024-03-14) .
| - | No. | Title | Protest days |
|---|---|---|---|
| 1 | 特表2021-527040 | カンプトテシンコンジュゲート | 2024-03-25 |
| 2 | 特表2023-546593 | ペットフード組成物 | 2024-03-14 |
| 3 | 特開2023-175938 | 糖代謝改善用組成物 | 2024-03-04 |
| 4 | 特表2023-531169 | 熱希釈作用および身体閉塞破壊作用の両方を有するカテーテル・システム、ならびに血流量を判定し、身体閉塞破壊を実行するための方法 | 2024-02-20 |
| 5 | 特開2023-175853 | 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法 | 2024-02-16 |
| 6 | 特許7038388 | 医療システム及びそれを実行する方法 | 2024-02-14 |
| 7 | 特開2023-029502 | 血流改善剤 | 2024-02-13 |
| 8 | 特表2023-534047 | オリゴ糖組成物及び使用方法 | 2024-02-07 |
| 9 | 特表2022-504702 | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 | 2024-01-30 |
| 10 | 特開2021-172726 | 微多孔フィルム | 2024-01-23 |
| 11 | 特開2023-052609 | 細胞培養物の製造方法 | 2024-01-23 |
| 12 | 特開2023-055917 | ＰＡＭＰＳ及びＤＡＭＰＳの除去への血液適合性多孔性ポリマービーズ吸着剤の使用 | 2024-01-17 |
| 13 | 特表2021-500373 | 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤 | 2024-01-12 |
| 14 | 特開2021-020855 | 血中尿酸値低下剤及び血中尿酸値低下用食品組成物 | 2023-12-20 |
| 15 | 特表2021-531738 | ケトン曝露を増加させるためのＭＣＴ製剤、並びにかかる製剤の製造及び使用方法 | 2023-11-28 |
| 16 | 特開2021-195715 | 経血透過性付与剤、繊維、不織布及び吸収性物品 | 2023-11-16 |
| 17 | 再公表2020/166700 | 血小板溶解物の製造方法、製造システム及びバッグセット | 2023-11-16 |
| 18 | 特開2021-019558 | 改良されたウイルス検出方法 | 2023-11-06 |
| 19 | 特開2021-019559 | 改良されたウイルス検出方法 | 2023-11-06 |
| 20 | 特許7391858 | ポリ硫酸化多糖類を用いた術後関節痛の処置 | 2023-09-28 |
Top Patents/Patent Applications with the Highest Number of Protested
Of the patent applications filed in the last 10 years (2014-05-01 to 2024-04-30), 188 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.4. The most protest patent is 特許7320919 "小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療" (10 times) , and the next most protest patent is 特開2017-006874 "血液処理器に用いられる膜モジュールのシール材用ポリウレタン樹脂形成性組成物" (6 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特許7320919 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 | 10 times |
| 2 | 特開2017-006874 | 血液処理器に用いられる膜モジュールのシール材用ポリウレタン樹脂形成性組成物 | 6 times |
| 3 | 特開2023-029502 | 血流改善剤 | 6 times |
| 4 | 特許7321480 | 組成物 | 5 times |
| 5 | 特許6564849 | 自動分析装置及び自動分析方法 | 4 times |
Inspectioned cases
List of latest Inspectioned patents
In the last 3 years (2021-05-01 ~ 2024-04-30), there were 569 patents Inspection from third parties. The average number of Inspection is 1.4 times. The most recently Inspection patent is 特表2021-505168 "操作されたＴ細胞の組成物を製造するための方法" (Inspection day 2024-03-26) , next is 特開2022-104994 "細胞培養のための細胞外マトリクス組成物ビーズ" (Inspection day 2024-03-26) .
| - | No. | Title | Inspection days |
|---|---|---|---|
| 1 | 特表2021-505168 | 操作されたＴ細胞の組成物を製造するための方法 | 2024-03-26 |
| 2 | 特開2022-104994 | 細胞培養のための細胞外マトリクス組成物ビーズ | 2024-03-26 |
| 3 | 特開2019-011372 | インターロイキン−６関連疾患の治療方法 | 2024-03-26 |
| 4 | 特表2024-502934 | 人工心臓弁装置、システム及び方法 | 2024-03-25 |
| 5 | 特表2021-517140 | マイクロバイオームの均衡をとるのに使用するための組成物 | 2024-03-21 |
| 6 | 特表2023-531169 | 熱希釈作用および身体閉塞破壊作用の両方を有するカテーテル・システム、ならびに血流量を判定し、身体閉塞破壊を実行するための方法 | 2024-03-21 |
| 7 | 特許5669730 | 針を安全に偏向させる装置 | 2024-03-19 |
| 8 | 特表2023-525436 | ビグアニド系化合物、及びフラボン、ヒドロキシフラボン、フラバノン、フラボン誘導体、ヒドロキシフラボン誘導体、フラバノン誘導体の複合剤を有効成分として含有する癌の予防または治療用薬学的組成物 | 2024-03-18 |
| 9 | 特表2023-528059 | 抗ウイルス剤及び抗うつ剤を有効成分として含有する癌の予防または治療用薬学的組成物 | 2024-03-18 |
| 10 | 特開2018-005928 | 最適化された栄養処方物、それらから目的に合わせた食事を選択するための方法、およびその使用法 | 2024-03-13 |
| 11 | 特表2021-529821 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 | 2024-03-13 |
| 12 | 特開2023-175938 | 糖代謝改善用組成物 | 2024-03-11 |
| 13 | 特開2023-175853 | 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法 | 2024-03-11 |
| 14 | 特表2021-514394 | 止血材 | 2024-03-11 |
| 15 | 特開2021-051749 | 最適化された栄養処方物、それらから目的に合わせた食事を選択するための方法、およびその使用法 | 2024-03-07 |
| 16 | 特許7038388 | 医療システム及びそれを実行する方法 | 2024-03-07 |
| 17 | 特開2022-081543 | 抗ＴＲＥＭ２抗体及びその使用方法 | 2024-02-27 |
| 18 | 特表2021-516222 | 副甲状腺ホルモンポリペプチドコンジュゲートおよびその使用方法 | 2024-02-20 |
| 19 | 特開2023-029502 | 血流改善剤 | 2024-02-19 |
| 20 | 特表2020-524139 | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 | 2024-02-16 |
Top Patents/Patent Applications with the Highest Number of Inspectioned
Of the patent applications filed in the last 10 years (2014-05-01 to 2024-04-30), 1,107 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.4. The most inspection patent is 特開2017-149726 "Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療" (46 times) , and the next most inspection patent is 特開2017-214435 "抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法" (43 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特開2017-149726 | Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療 | 46 times |
| 2 | 特開2017-214435 | 抗ＣＤ２０抗体の投与を含むＢ細胞リンパ腫の併用療法 | 43 times |
| 3 | 特許7320919 | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 | 20 times |
| 4 | 特開2015-016345 | 新アルカリ性電子エナジー | 19 times |
| 5 | 特許6225270 | 粒度調整された炭酸ランタン水和物からなる医薬 | 9 times |
Cited cases
Top Patents/Patent Applications with the Highest Number of Cited
Of the patent applications filed in the last 10 years (2014-05-01 to 2024-04-30), 5,388 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.5. The most cited patent is 特開2014-217381 "ｍｉＲＮＡおよびｍｉＲＮＡ阻害分子に関する方法および組成物" (68 times) , and the next most cited patent is 特許6594413 "携帯デバイスを介する非侵襲的神経刺激" (57 times) .
| - | No. | Title | |
|---|---|---|---|
| 1 | 特開2014-217381 | ｍｉＲＮＡおよびｍｉＲＮＡ阻害分子に関する方法および組成物 | 68 times |
| 2 | 特許6594413 | 携帯デバイスを介する非侵襲的神経刺激 | 57 times |
| 3 | 特許6659831 | 生体情報分析装置、システム、及び、プログラム | 50 times |
| 4 | 特許6683367 | 生体情報計測装置、生体情報計測方法及び生体情報計測プログラム | 41 times |
| 5 | 特許6203410 | 患者固有の解剖学的構造の画像データから冠動脈プラークの脆弱性を予測するシステム及びシステムの作動方法 | 41 times |
Providing patent information to the media (newspapers, magazines, etc.)
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
About this Site
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
Please note the following points for use.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
Citation of patent application status and ranking information
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Graphs are image data.
Please note that the various graphs are image data, but we cannot provide them in text data.Scope of coverage for each goal/target
- Based on the description of each goal and target of the SDGs, we have set the scope of technologies to be covered based on our and e-Patent's past experience, etc. (in some cases, the search is based on social issues themselves). Therefore, please note that there is a possibility that this "SDGs Global Company Ranking from Patent Perspective" may not cover 100%.
- A population search formula is clearly indicated for each goal/target (database: Patent Integration). You may use the population search formula as it is, or you may improve it by yourself.
- This search covers patents and utility models, including both published and registered patents (design and design patents are excluded). The unit of count is the number of applications, not the number of patent families.
About the name collation and name control of applicants and right holders
- Company rankings are based on the results calculated by "Patent Integration", with Japanese organizations in Japanese and other companies in English (some are in Japanese).
- Company names may be the names of the companies at the time of application, but the results calculated by Patent Integration are used as is. Company names are used as they were at the time of application.
- Because of the fluctuation in the names of companies (i.e., applicant/right holder names in the patent information), there are cases where the same company appears more than once in the top 10. The number of applications filed by the same company in the top 10 is the total number of applications filed by the company.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International
Our Commitment to Safety and Security
Patent Integration Co., Ltd. is committed to providing high-quality patent information based on the latest patent data on more than 45 million cases collected from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publication. 
Patent Integration Co., Ltd. collects the patent data from the Patent Offices in Japan, the U.S., Europe, and Taiwan and from PCT publications to provide it widely in the form of reports so that anyone can check patent information and patent trends with confidence. 
Patent Integration Co., Ltd. is committed to various efforts to enhance the reliability of the information and to allow users to search patent information with confidence.